The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

• Status: Completed
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborators: Aarhus University Hospital; Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Informed consent

• Diagnosis of type 2 diabetes (HbA1c > 48 mmol/mol)

• Age older than 30 years

Exclusion Criteria:

• Type 1 diabetes

• Treatment with insulin

• Body weight > 140 kg

• HbA1c > 75 mmol/mol

• Treatment with GLP-1 analogues, Dipeptidyl peptidase-4 inhibitors, or glitazones

• Chronic kidney disease

• Hepatic disease

• Pancreatitis

• Inflammatory bowel disease

• Osteoporosis

• Family or personal history of medullary thyroid carcinoma

• Treatment with glucocorticoids

• Hormone replacement therapy

• Diabetic gastroparesis

• Pregnancy or lactation